Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Hits Expectations

Lifecore Biomedical (NASDAQ:LFCR) posted its earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19), FiscalAI reports. The firm had revenue of $34.17 million during the quarter, compared to the consensus estimate of $33.83 million.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance for revenue of $120 million–$125 million and adjusted EBITDA of $20.5 million–$25 million, with stronger CDMO revenue expected in the second half, particularly in Q4.
• Contractually committed fill-finish demand from Lifecore’s largest customer is expected to double in 2027 and increase more than 200% in 2028 versus 2026, while a successful PMDA inspection supports potential expansion into Japan.
• The company added six pipeline programs during the quarter and nine year-to-date, including late-stage and commercial site-transfer opportunities; management believes 11 existing development programs could commercialize by the end of 2028.
• Second-quarter revenue fell 6.2% to $34.2 million, while six-month revenue declined 19.9% to $57.4 million; adjusted EBITDA decreased to $8.6 million in the quarter and $9.6 million for the six-month period, and the quarterly net loss widened to $6.2 million.
• Liquidity improved to approximately $38.8 million, but potential Series A preferred payments are not due until December 2028 and would require lender approval; unpaid amounts would accrue interest at 1% per month.

Lifecore Biomedical Stock Performance

NASDAQ LFCR traded up $0.07 during trading on Friday, hitting $4.91. The stock had a trading volume of 67,792 shares, compared to its average volume of 238,446. The company has a market capitalization of $184.32 million, a PE ratio of -4.59 and a beta of 1.08. Lifecore Biomedical has a 12 month low of $3.63 and a 12 month high of $8.98. The company’s 50-day moving average price is $5.03 and its two-hundred day moving average price is $5.58.

Institutional Trading of Lifecore Biomedical

Large investors have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in Lifecore Biomedical in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its position in Lifecore Biomedical by 92.7% during the third quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock worth $43,000 after purchasing an additional 2,786 shares during the period. State of Wyoming acquired a new position in shares of Lifecore Biomedical in the second quarter valued at $69,000. The Manufacturers Life Insurance Company bought a new position in shares of Lifecore Biomedical in the second quarter valued at about $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after purchasing an additional 1,886 shares during the period. Institutional investors and hedge funds own 83.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Barrington Research raised their price target on Lifecore Biomedical from $6.00 to $6.50 and gave the company an “outperform” rating in a report on Tuesday, June 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lifecore Biomedical in a research note on Tuesday. Zacks Research upgraded shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Lifecore Biomedical has an average rating of “Hold” and an average price target of $6.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.